LRRK2 and Parkinson disease: In our country, this age of onset is older than that previously reported in Parkinson's disease in a large Tunisian cohort of 226 PD, either in patients with LRRK2 G2019S mutation (with an average of 53.8 years) or in G2019S noncarriers (with an average of 57.5 years) (Ben Romdhan et al., 2018).